182 related articles for article (PubMed ID: 35037146)
1. Targeting mitochondrial dysfunction with elamipretide.
Obi C; Smith AT; Hughes GJ; Adeboye AA
Heart Fail Rev; 2022 Sep; 27(5):1925-1932. PubMed ID: 35037146
[TBL] [Abstract][Full Text] [Related]
2. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K
Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394
[TBL] [Abstract][Full Text] [Related]
3. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.
Daubert MA; Yow E; Dunn G; Marchev S; Barnhart H; Douglas PS; O'Connor C; Goldstein S; Udelson JE; Sabbah HN
Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29217757
[TBL] [Abstract][Full Text] [Related]
4. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial.
Butler J; Khan MS; Anker SD; Fonarow GC; Kim RJ; Nodari S; O'Connor CM; Pieske B; Pieske-Kraigher E; Sabbah HN; Senni M; Voors AA; Udelson JE; Carr J; Gheorghiade M; Filippatos G
J Card Fail; 2020 May; 26(5):429-437. PubMed ID: 32068002
[TBL] [Abstract][Full Text] [Related]
5. The cardiolipin-binding peptide elamipretide mitigates fragmentation of cristae networks following cardiac ischemia reperfusion in rats.
Allen ME; Pennington ER; Perry JB; Dadoo S; Makrecka-Kuka M; Dambrova M; Moukdar F; Patel HD; Han X; Kidd GK; Benson EK; Raisch TB; Poelzing S; Brown DA; Shaikh SR
Commun Biol; 2020 Jul; 3(1):389. PubMed ID: 32680996
[TBL] [Abstract][Full Text] [Related]
6. Abnormalities of Mitochondrial Dynamics in the Failing Heart: Normalization Following Long-Term Therapy with Elamipretide.
Sabbah HN; Gupta RC; Singh-Gupta V; Zhang K; Lanfear DE
Cardiovasc Drugs Ther; 2018 Aug; 32(4):319-328. PubMed ID: 29951944
[TBL] [Abstract][Full Text] [Related]
7. Effects of elamipretide on skeletal muscle in dogs with experimentally induced heart failure.
Sabbah HN; Gupta RC; Singh-Gupta V; Zhang K
ESC Heart Fail; 2019 Apr; 6(2):328-335. PubMed ID: 30688415
[TBL] [Abstract][Full Text] [Related]
8. Elamipretide Promotes Mitophagosome Formation and Prevents Its Reduction Induced by Nutrient Excess in INS1 β-cells.
Petcherski A; Trudeau KM; Wolf DM; Segawa M; Lee J; Taddeo EP; Deeney JT; Liesa M
J Mol Biol; 2018 Dec; 430(24):4823-4833. PubMed ID: 30389435
[TBL] [Abstract][Full Text] [Related]
9. Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid.
Sabbah HN
Heart Fail Rev; 2022 Sep; 27(5):1911-1923. PubMed ID: 34623544
[TBL] [Abstract][Full Text] [Related]
10. The effects of a mitochondrial targeted peptide (elamipretide/SS31) on BAX recruitment and activation during apoptosis.
Grosser JA; Fehrman RL; Keefe D; Redmon M; Nickells RW
BMC Res Notes; 2021 May; 14(1):198. PubMed ID: 34022923
[TBL] [Abstract][Full Text] [Related]
11. Elamipretide Improves Mitochondrial Function in the Failing Human Heart.
Chatfield KC; Sparagna GC; Chau S; Phillips EK; Ambardekar AV; Aftab M; Mitchell MB; Sucharov CC; Miyamoto SD; Stauffer BL
JACC Basic Transl Sci; 2019 Apr; 4(2):147-157. PubMed ID: 31061916
[TBL] [Abstract][Full Text] [Related]
12. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
Reid Thompson W; Hornby B; Manuel R; Bradley E; Laux J; Carr J; Vernon HJ
Genet Med; 2021 Mar; 23(3):471-478. PubMed ID: 33077895
[TBL] [Abstract][Full Text] [Related]
13. The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.
Hortmann M; Robinson S; Mohr M; Mauler M; Stallmann D; Reinöhl J; Duerschmied D; Peter K; Carr J; Gibson CM; Bode C; Ahrens I
Eur Heart J Acute Cardiovasc Care; 2019 Dec; 8(8):695-702. PubMed ID: 28534645
[TBL] [Abstract][Full Text] [Related]
14. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis.
Saad A; Herrmann SMS; Eirin A; Ferguson CM; Glockner JF; Bjarnason H; McKusick MA; Misra S; Lerman LO; Textor SC
Circ Cardiovasc Interv; 2017 Sep; 10(9):. PubMed ID: 28916603
[TBL] [Abstract][Full Text] [Related]
15. Myocardial Energetics and Heart Failure: a Review of Recent Therapeutic Trials.
Bhatt KN; Butler J
Curr Heart Fail Rep; 2018 Jun; 15(3):191-197. PubMed ID: 29707741
[TBL] [Abstract][Full Text] [Related]
16. Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice.
Zhao W; Xu Z; Cao J; Fu Q; Wu Y; Zhang X; Long Y; Zhang X; Yang Y; Li Y; Mi W
J Neuroinflammation; 2019 Nov; 16(1):230. PubMed ID: 31747905
[TBL] [Abstract][Full Text] [Related]
17. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
Hornby B; Thompson WR; Almuqbil M; Manuel R; Abbruscato A; Carr J; Vernon HJ
Orphanet J Rare Dis; 2022 Sep; 17(1):336. PubMed ID: 36056411
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Functional Mitral Regurgitation Severity in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF).
Naser N
Med Arch; 2022 Feb; 76(1):17-22. PubMed ID: 35422569
[TBL] [Abstract][Full Text] [Related]
19. Intermittent treatment with elamipretide preserves exercise tolerance in aged female mice.
Campbell MD; Samuelson AT; Chiao YA; Sweetwyne MT; Ladiges WC; Rabinovitch PS; Marcinek DJ
Geroscience; 2023 Aug; 45(4):2245-2255. PubMed ID: 36840897
[TBL] [Abstract][Full Text] [Related]
20. Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.
Koenig MK; Russo SN; McBride KL; Bjornsson HT; Gunnarsdottir BB; Goldstein A; Falk SA
JIMD Rep; 2023 Jan; 64(1):65-70. PubMed ID: 36636586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
